Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade
Liangliang Wang, Yan Gao, Gao Zhang, Dan Li, Zhenda Wang, Jie Zhang, Leandro C. Hermida, Lei He, Zhisong Wang, Jingwen Si, Shuang Geng, Rizi Ai, Fei Ning, Chaoran Cheng, Haiteng Deng, Dimiter S. Dimitrov, Yan Sun, Yanyi Huang, Dong Wang, Xiaoyu Hu, Zhi Wei, Wei Wang, Xuebin Liao
Abstract
expression and could potentially serve as a marker of response to anti-PD-1 immunotherapy. Furthermore, our results indicated that bifunctional agents that enhance both KDM5A and TLR activity warrant investigation as combination therapies with ICB agents.
Topics & Concepts
BlockadeImmune checkpointTLR7Cancer researchImmune systemMedicineImmunologyInnate immune systemReceptorInternal medicineToll-like receptorCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionCancer therapeutics and mechanisms